Bionano Genomics Inc. [NASDAQ: BNGO] slipped around -0.06 points on Friday, while shares priced at $7.58 at the close of the session, down -0.79%. The company report on June 7, 2021 that Bionano Genomics Appoints Jason Priar, Former GeneDx, Sema4 and PerkinElmer Genomics Sales Leader, as its Chief Commercial Officer.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced that Jason Priar has joined the company as its Chief Commercial Officer. Jason is a seasoned sales leader with experience scaling businesses from early stage to hundreds of millions in revenue. He has a deep understanding of how to penetrate clinical and research markets including genetic diseases and cancer. For Bionano, he will lead the commercial teams across the platform and services businesses to drive sales and market access with third party payors.
“We are thrilled to welcome Jason to Bionano. We believe he has the experience in scaling revenues and obtaining market access from third party payers that we need to accelerate global adoption of optical genome mapping (OGM) with our Saphyr® system and drive Lineagen’s business of providing diagnostic services in pediatric neurodevelopmental disorders,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “Jason’s intimate familiarity with the needs of traditional cytogenomics laboratories performing genome analysis in cancer and genetic diseases, combined with his understanding of needs of the physicians and pharmaceutical partners who apply the data, is among the best I have encountered in the industry. I believe adding Jason to an already stellar team can have a profound impact on Bionano.”.
Bionano Genomics Inc. stock is now 146.10% up from its year-to-date (YTD) trading value. BNGO Stock saw the intraday high of $7.88 and lowest of $7.51 per share. The company’s 52-week high price is 15.69, which means current price is +93.86% above from all time high which was touched on 02/16/21.
Compared to the average trading volume of 24.10M shares, BNGO reached a trading volume of 12347957 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Bionano Genomics Inc. [BNGO]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BNGO shares is $12.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BNGO stock is a recommendation set at 1.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Ladenburg Thalmann have made an estimate for Bionano Genomics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 24, 2020. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on April 08, 2020, representing the official price target for Bionano Genomics Inc. stock.
The Average True Range (ATR) for Bionano Genomics Inc. is set at 0.69, with the Price to Sales ratio for BNGO stock in the period of the last 12 months amounting to 202.90. The Price to Book ratio for the last quarter was 5.53, with the Price to Cash per share for the same quarter was set at 1.29.
How has BNGO stock performed recently?
Bionano Genomics Inc. [BNGO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 10.33. With this latest performance, BNGO shares gained by 59.92% in over the last four-week period, additionally plugging by 1392.42% over the last 6 months – not to mention a rise of 1373.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BNGO stock in for the last two-week period is set at 60.63, with the RSI for the last a single of trading hit 63.13, and the three-weeks RSI is set at 57.06 for Bionano Genomics Inc. [BNGO]. The present Moving Average for the last 50 days of trading for this stock 6.34, while it was recorded at 7.94 for the last single week of trading, and 4.72 for the last 200 days.
Bionano Genomics Inc. [BNGO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Bionano Genomics Inc. [BNGO] shares currently have an operating margin of -435.74 and a Gross Margin at +21.67. Bionano Genomics Inc.’s Net Margin is presently recorded at -483.43.
Return on Total Capital for BNGO is now -98.66, given the latest momentum, and Return on Invested Capital for the company is -149.42. Return on Equity for this stock declined to -212.46, with Return on Assets sitting at -90.69. When it comes to the capital structure of this company, Bionano Genomics Inc. [BNGO] has a Total Debt to Total Equity ratio set at 46.54. Additionally, BNGO Total Debt to Total Capital is recorded at 31.76, with Total Debt to Total Assets ending up at 27.01. Long-Term Debt to Equity for the company is recorded at 46.54, with the Long-Term Debt to Total Capital now at 31.76.
Reflecting on the efficiency of the workforce at the company, Bionano Genomics Inc. [BNGO] managed to generate an average of -$279,635 per employee. Receivables Turnover for the company is 1.87 with a Total Asset Turnover recorded at a value of 0.19.Bionano Genomics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 51.20 and a Current Ratio set at 51.60.
Earnings analysis for Bionano Genomics Inc. [BNGO]
With the latest financial reports released by the company, Bionano Genomics Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.09/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BNGO.
Insider trade positions for Bionano Genomics Inc. [BNGO]
There are presently around $328 million, or 15.50% of BNGO stock, in the hands of institutional investors. The top three institutional holders of BNGO stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 9,486,494, which is approximately New of the company’s market cap and around 0.30% of the total institutional ownership; VANGUARD GROUP INC, holding 9,295,839 shares of the stock with an approximate value of $70.46 million in BNGO stocks shares; and INVESCO LTD., currently with $31.78 million in BNGO stock with ownership of nearly New of the company’s market capitalization.
Positions in Bionano Genomics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 112 institutional holders increased their position in Bionano Genomics Inc. [NASDAQ:BNGO] by around 32,171,198 shares. Additionally, 17 investors decreased positions by around 1,434,823 shares, while 2 investors held positions by with 9,616,434 shares. The mentioned changes placed institutional holdings at 43,222,455 shares, according to the latest SEC report filing. BNGO stock had 84 new institutional investments in for a total of 20,000,393 shares, while 12 institutional investors sold positions of 318,575 shares during the same period.